{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:14:38Z","timestamp":1793103278109,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Electrocardiology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jelectrocard.2019.12.007","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T08:37:26Z","timestamp":1576485446000},"page":"20-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Tp-e interval and Tp-e\/QT ratio and their association with left ventricular diastolic dysfunction in Fabry disease without left ventricular hypertrophy"],"prefix":"10.1016","volume":"59","author":[{"given":"Mustafa","family":"Yener\u00e7a\u011f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U\u011fur","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0005","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under recognized multisystemic disorder: expert recommendations for diagnosis, management and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","article-title":"European expert consensus statement on therapeutic goals in Fabry disease","volume":"124","author":"Wanner","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0015","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jjcc.2007.12.001","article-title":"Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study","volume":"51","author":"Takenaka","year":"2008","journal-title":"J Cardiol"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fcvm.2016.00007","article-title":"Electrocardiographic changes and arrhythmia in Fabry disease","volume":"3","author":"Namdar","year":"2016","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0025","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/01.hco.0000131534.25034.43","article-title":"Tissue Doppler imaging in Fabry disease","volume":"19","author":"Pieroni","year":"2004","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0035","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.amjcard.2014.06.019","article-title":"Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease","volume":"114","author":"Kr\u00e4mer","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0040","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jiph.2017.02.008","article-title":"Tp-e interval and Tp-e\/QT ratio in patients with Human Immunodeficiency Virus","volume":"11","author":"\u00dcnal","year":"2018","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0050","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jelectrocard.2018.07.016","article-title":"The effect of moderate altitude on Tp-e interval, Tp-e\/QT, QT, QTc and P-wave dispersion","volume":"51","author":"Akcay","year":"2018","journal-title":"J Electrocardiol"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0055","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/0735-1097(95)00122-G","article-title":"Dispersion of QT interval in patients with and without susceptibility to ventricular tachyarrhythmias after previous myocardial infarction","volume":"26","author":"Perki\u00f6m\u00e4ki","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0060","first-page":"353","article-title":"An analysis of the time-relations of electrocardiograms","volume":"7","author":"Bazett","year":"1920","journal-title":"Heart"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0065","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0002-9149(86)90771-X","article-title":"Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings","volume":"57","author":"Devereux","year":"1986","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0070","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0075","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.acvd.2019.01.002","article-title":"Fabry disease in cardiology practice: literature review and expert point of view","volume":"112","author":"Hag\u00e8ge","year":"2019","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/7b2c04df-8592-4fb7-8608-3039db28b504","article-title":"Globotriaosylsphingosine accumulation and not alpha\u2013galactosidase\u2013A deficiency causes endothelial dysfunction in Fabry disease","volume":"7","author":"Namdar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0085","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.humpath.2015.07.017","article-title":"Increased oxidative stress contributes to cardiomyocyte dysfunction and death in patients with Fabry disease cardiomyopathy","volume":"46","author":"Chimenti","year":"2015","journal-title":"Hum Pathol"},{"issue":"FI2","key":"10.1016\/j.jelectrocard.2019.12.007_bb0090","doi-asserted-by":"crossref","first-page":"f153","DOI":"10.1093\/europace\/eux261","article-title":"Ventricular arrhythmia and sudden cardiac death in Fabry disease:a systematic review of risk factors in clinical practice","volume":"20","author":"Baig","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0095","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J Med Genet"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0100","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0105","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/CIRCEP.114.002569","article-title":"Pathology and function of conduction tissue in Fabry disease cardiomyopathy","volume":"8","author":"Frustaci","year":"2015","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0110","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jelectrocard.2008.07.030","article-title":"The meaning of the Tp\u2013Te intervaland its diagnostic value","volume":"41","author":"Kors","year":"2008","journal-title":"J Electrocardiol"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0115","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.jacc.2005.12.049","article-title":"Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia\/ventricular fibrillation in patients with the Brugada syndrome","volume":"47","author":"Castro Hevia","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0120","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/hrt.2010.211789","article-title":"Electrocardiographic changes in early recognition of Fabry disease","volume":"97","author":"Namdar","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0125","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1540-8175.2012.01704.x","article-title":"Systolic myocardial mechanics in patients with Anderson-Fabry disease with and without left ventricular hypertrophy and in comparison to nonobstructive hypertrophic cardiomyopathy","volume":"29","author":"Gruner","year":"2012","journal-title":"Echocardiography"},{"key":"10.1016\/j.jelectrocard.2019.12.007_bb0130","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1161\/01.CIR.99.2.254","article-title":"Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy","volume":"99","author":"Nagueh","year":"1999","journal-title":"Circulation"}],"container-title":["Journal of Electrocardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022073619307976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022073619307976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T12:29:58Z","timestamp":1758284998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022073619307976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":26,"alternative-id":["S0022073619307976"],"URL":"https:\/\/doi.org\/10.1016\/j.jelectrocard.2019.12.007","relation":{},"ISSN":["0022-0736"],"issn-type":[{"value":"0022-0736","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tp-e interval and Tp-e\/QT ratio and their association with left ventricular diastolic dysfunction in Fabry disease without left ventricular hypertrophy","name":"articletitle","label":"Article Title"},{"value":"Journal of Electrocardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jelectrocard.2019.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}